Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan.
National Institute of Health Sciences, Kawasaki, Kanagawa 210-9501, Japan.
Mol Pharm. 2021 Apr 5;18(4):1711-1719. doi: 10.1021/acs.molpharmaceut.0c01207. Epub 2021 Feb 25.
An in vitro methodology for simulating the change in the pH and composition of gastrointestinal fluid associated with the transition of orally administered drugs from the stomach to the small intestine was developed (the stomach-to-intestine fluid changing system (the SIFC system)). This system was applied to in vitro sensitivity analysis on the dissolution of weakly basic drugs, and the obtained results were discussed in relation to the intrasubject variability in the plasma exposure in human bioequivalence (BE) study. Three types of protocols were employed (steep pH change: pH 1.6 FaSSGF → pH 6.5 FaSSIF, gradual pH change: pH 1.6 FaSSGF → pH 6.5 FaSSIF, and high gastric pH: pH 4.0 FaSSGF → pH 6.5 FaSSIF). Regardless of the protocols and the forms of drug applied in active pharmaceutical ingredient powder or formulation, dissolution profiles of pioglitazone after fluid shift were similar and the final concentrations in FaSSIF were approximately equal to the saturation solubility in FaSSIF, supporting its small intrasubject variance in human BE study. In contrast, dissolved concentration of terbinafine in the SIFC system became less than half in the high gastric pH protocol than that in other protocols, suggesting the fluctuation of gastric pH as one of the factors of high intrasubject variance of terbinafine in human. Plasma exposure of telmisartan was highly variable especially at the high dose. Although the dissolution of telmisartan in the SIFC system was greatly improved by formulation, it considerably fluctuated during fluid shift especially at the high dose, which corresponds well to in vivo results.
开发了一种模拟与口服药物从胃到小肠的转变相关的胃肠道液 pH 值和组成变化的体外方法学(胃到肠液变化系统(SIFC 系统))。该系统应用于弱碱性药物溶解的体外敏感性分析,并将获得的结果与人体生物等效性(BE)研究中血浆暴露的个体内变异性相关联进行了讨论。采用了三种方案(急剧 pH 值变化:pH 1.6 FaSSGF→pH 6.5 FaSSIF、逐渐 pH 值变化:pH 1.6 FaSSGF→pH 6.5 FaSSIF 和高胃 pH 值:pH 4.0 FaSSGF→pH 6.5 FaSSIF)。无论应用于原料药粉末还是制剂的药物形式和方案如何,吡格列酮在流体转移后的溶解曲线相似,FaSSIF 中的最终浓度近似等于 FaSSIF 中的饱和溶解度,支持其在人体 BE 研究中个体内变异性较小。相比之下,在高胃 pH 值方案中,特比萘芬在 SIFC 系统中的溶解浓度比其他方案中的溶解浓度低一半,表明胃 pH 值的波动是特比萘芬个体内变异性高的因素之一。替米沙坦的血浆暴露高度可变,尤其是高剂量时。尽管替米沙坦在 SIFC 系统中的溶解通过配方得到了极大改善,但在流体转移过程中特别是在高剂量时,其变化很大,这与体内结果相符。